EcoDrugPlus

Akt Serine/threonine Kinase 3

Ensembl ID : ENSMODG00000006626
Gene Symbol: AKT3
5 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSMODG00000008491
Gene Symbol: AXL
5 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSMODG00000013637
Gene Symbol: BRAF
2 Cross references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bcl2 Like 10

Ensembl ID : ENSMODG00000001950
Gene Symbol: BCL2L10
4 Cross references
129 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bcl2 Related Protein A1

Ensembl ID : ENSMODG00000019429
Gene Symbol: BCL2A1
5 Cross references
114 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bruton Tyrosine Kinase

Ensembl ID : ENSMODG00000011651
Gene Symbol: BTK
2 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-C Chemokine Receptor Type 5-Like

Ensembl ID : ENSMODG00000042135
Gene Symbol: LOC100030002
3 Cross references
369 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-C Motif Chemokine Receptor 1

Ensembl ID : ENSMODG00000011451
Gene Symbol: CCR1
4 Cross references
299 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSMODG00000010830
Gene Symbol: CCR4
4 Cross references
254 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSMODG00000011402
Gene Symbol: CCR9
2 Cross references
262 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-X-C Chemokine Receptor Type 1

Ensembl ID : ENSMODG00000046410
Gene Symbol: LOC100012266
4 Cross references
274 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-X-C Chemokine Receptor Type 2

Ensembl ID : ENSMODG00000015510
Gene Symbol: LOC100012302
4 Cross references
274 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).